U.S. markets open in 5 hours 46 minutes

CureVac N.V. (CVAC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
94.30+1.33 (+1.43%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Previous Close92.97
Open94.79
Bid0.00 x 800
Ask0.00 x 1000
Day's Range92.08 - 96.71
52 Week Range36.15 - 151.80
Volume514,203
Avg. Volume789,088
Market Cap17.626B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • 15 Fastest Growing Biotech Companies in the US
    Insider Monkey

    15 Fastest Growing Biotech Companies in the US

    In this article we talk about 15 fastest growing biotech companies in the US. You can skip our detailed analysis of the biotech industry and go to 5 Fastest Growing Biotech Companies in the US. Biotechnology is one of the most consequential domains of the healthcare industry. Biotechnology uses biology and the functions of living […]

  • Johnson & Johnson's COVID-19 Vaccine Likely To Get EU Approval Early March: Bloomberg
    Benzinga

    Johnson & Johnson's COVID-19 Vaccine Likely To Get EU Approval Early March: Bloomberg

    The European Medical Agency (EMA) is reportedly set to recommend Johnson & Johnson’s (NYSE: JNJ) coronavirus vaccine on March 11, according to Bloomberg. The European Commission said deliveries of the J&J shot are expected to begin in early April, thus bolstering the supplies over the second and third quarters. The EU inked a purchase deal with JNJ to supply doses for 200 million people, with an option for an additional 200 million. The EU official also said that the agency is in talks with Russian authorities on the Sputnik V vaccine and may receive data soon to begin a rolling review process. The EMA is also carrying out a rolling review of the CureVac BV (NASDAQ: CVAC) and Novavax Inc (NASDAQ: NVAX) shots. The European Commission has agreed to purchase 225 million CureVac shots and 100 million doses from Novavax. On Wednesday, the FDA backed the JNJ’s single-shot COVID-19 vaccine, which protected from the infection after receiving the vaccine. The FDA Adcom meeting to review JNJ’s shot is scheduled today. Price Action: JNJ shares are up by 0.28% at $163.21, NVAX shares are down 1.4% at $218.4, and CVAC shares are up 1.5% at $94.36 in the premarket session on the last check Friday. See more from BenzingaClick here for options trades from BenzingaModerna Raises 2021 Base COVID-19 Vaccine Production Plan To 700M DosesModerna To Test New COVID-19 Vaccine Targeting South Africa Strain© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • The Johnson & Johnson Vaccine Has Competition in the Race to Treat New Strains
    Motley Fool

    The Johnson & Johnson Vaccine Has Competition in the Race to Treat New Strains

    You might have thought the coronavirus vaccine race ended when Pfizer (NYSE: PFE) crossed the finish line first in December. Variants from Brazil, the U.K., and South Africa worry the scientific community (and the rest of us) the most at the moment. Johnson & Johnson (NYSE: JNJ) highlighted exactly how its investigational vaccine performed against those new strains in its phase 3 trial.